Eli Lilly and Galapagos initiated their alliance to develop new medicines for the treatment of osteoporosis in 2008.
The alliance agreement provides Lilly access to 12 of Galapagos’ new target based programs in osteoporosis, with Galapagos responsible for the development of drug candidates through to Phase IIa clinical Proof of Concept.
To date, Galapagos has received a total of EUR9.8m in payments from Lilly under the alliance.
Onno van de Stolpe, CEO of Galapagos, said: “Our drug discovery approach has shown progress despite the challenges intrinsic to working in the osteoporosis field.
“The molecules that we have identified thus far show bone-building properties and we are further optimising these molecules to deliver orally-available small molecules to Lilly’s development team.”